Enhanced Cationic Amphiphilic Polymers for Efficient Codelivery of Hydrophobic Agents and Nucleic Acids

An improved system for codelivery of hydrophobic agents and nucleic acids, utilizing enhanced cationic amphiphilic polymers with improved solubility, higher cationic charge density, and targeted delivery capabilities.

The original patent, 'Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids,' disclosed a formulation for codelivery of hydrophobic agents and nucleic acids. However, the original patent's polymers may have limited solubility in water and binding affinity with nucleic acids, resulting in inefficient delivery. The new inventive concept addresses these limitations by introducing improved polymers synthesized using controlled radical polymerization methods, modified to have higher cationic charge density, and optimized for targeted delivery.

The enhanced cationic amphiphilic polymers are synthesized using controlled radical polymerization methods, such as living radical polymerization, to achieve improved solubility in water. The polymers are modified to have a higher cationic charge density, resulting in improved binding affinity with nucleic acids. The system for codelivery comprises these enhanced polymers, a hydrophobic agent, and a nucleic acid. The method for preparing the formulation involves mixing the polymers with the hydrophobic agent and nucleic acid, and optimizing the formulation for targeted delivery to specific cells or tissues using a ligand-mediated delivery approach. A kit for codelivery is also provided, comprising the enhanced polymers, a hydrophobic agent, and a nucleic acid, designed for use in a specific disease treatment.

The new claims introduce several novel features, including the use of controlled radical polymerization methods to synthesize polymers with improved solubility, modification of polymers to have higher cationic charge density, and optimization of the formulation for targeted delivery. These features are non-obvious compared to the original patent and provide a significant improvement in the efficiency of codelivery.

Alternative embodiments of the inventive concept may include the use of different controlled radical polymerization methods, such as atom transfer radical polymerization or reversible addition-fragmentation chain transfer polymerization. Variations of the polymers may include different types of cationic groups, such as quaternary ammonium or phosphonium groups, or different types of nucleic acids, such as siRNA or microRNA.

The enhanced cationic amphiphilic polymers have significant commercial potential in the field of gene therapy and targeted drug delivery. The market for gene therapy is rapidly growing, and the inventive concept's ability to efficiently codeliver hydrophobic agents and nucleic acids could provide a competitive advantage in this market.